trial

Effect of Switch to Aripiprazole on Health and Smoking Parameters in Patients With Schizophrenia: A Pilot Study

NCTId NCT00167817
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 15
Sponsored by Veterans Medical Research Foundation
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
15
Study type
Interventional
Allocation
Non Randomized
Model
Single Group
Masking
None
Start
2003-07
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Aripiprazole

Sponsors

Veterans Medical Research FoundationLead Sponsor

Investigators

1
Jonathan M. Meyer, MDPrincipal Investigator

Sites

1 total
San Diego, United States

Facts & assertions

3 sourced
Enrollment
15
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Aripiprazole
drug
lead_sponsor
Veterans Medical Research Foundation
company
indication
Smoking
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Jonathan M. Meyer, MD
person